



Dennis Guberski
Founder

Dennis Guberski is the founder, Managing Partner, and President of MVT. The company maintains all the vaccine technologies, patents and intellectual properties once held by Biomere. Dennis was also the founder, CEO and most recently the Chairman of Biomere, a company he created as a 1996 spin-out of UMass Medical School. His Biotechnology experience includes more than 43 years, including 23 at the helm of Biomere and 20 years in the Pathology Department of the University of Massachusetts Medical School, both as a researcher and as the Director of the SPF vivarium.

A recognized expert on the development and maintenance of specialized research models Guberski was the first to identify Parvovirus initiation of Type 1 diabetes. He also developed a premier system to study diabetic complications. Dennis served as the Principal Investigator on the NIDDK Preclinical Testing Program for Type 1 Diabetes in support of the Institute's Raid contract (Rapid Access to Intervention Development T1D Raid). Under his guidance, Biomere grew from a startup to over 125 employees. Biomere's contract research organization business was sold to Joynn LTD in 2019.

Guberski has both been awarded and served as PI on numerous grants from the National Institutes of Health (NIH). He has also been a coinvestigator on projects from the CDC.

Dennis has authored dozens of peer reviewed publications, authored book chapters and is the coinventor on more than 20 vaccine patents.